Spyre Therapeutics, Inc. (SYRE) Dividend History

Company News

• Spyre Therapeutics Announces Grants of Inducement Awards

  Spyre Therapeutics granted stock options to five non-executive employees under its 2018 Equity Inducement Plan, with options vesting over four years and an exercise price of $16.26 per share.

  GlobeNewswire Inc.
• NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday

  U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. Shares of NIO Inc. (NYSE: NIO) rose during Tuesday’s session following upbeat quarterly results. NIO reported fourth-quarter revenue of 17.10 billion yuan ($2.41 billion), up by 6.5% year-over-year and down by 10.3% from the previous quarter. Analysts, on average, estimated revenue of $2.29 billion for the quarter. Excluding share-based compensation expenses, the company reported an adjusted loss of (2.81) yuan or ($0.39) compared to (3.07) yuan in the year-ago quarter and (2.28) yuan in the third quarter of 2023. Analysts had called for a loss of $(0.51) per share. NIO shares gained 3.6% to $5.52 on Tuesday. Here are some other big stocks recording gains in today’s session. Apogee Therapeutics, Inc. (NASDAQ: APGE) shares gained 41.6% to $59.10 after the company announced interim results from its Phase 1 healthy volunteer trial for APG777. Also, the company reported FY23 financial results. Dave ...

  Benzinga

  Featured Companies: APGE AVAV CEG DAVE DDD DVA HOG KRYS PAY REAL RSKD SRRK VVX
• Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength

  Spyre Therapeutics (SYRE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

  Zacks Investment Research